Samsung Bioepis Expands Sandoz Partnership – Global Deal for Five Biosimilars Including Entyvio Copycat SB36
Samsung Bioepis Co., Ltd. has expanded its strategic partnership with Sandoz AG (SWX: SDZ), entering...
Samsung Bioepis
Samsung Bioepis Announces Global ADC Collaboration with Phrontline Biopharma to Advance TJ108
Samsung Bioepis Co., Ltd. today announced a strategic, worldwide partnership with Phrontline Biopharma to jointly develop,...
Sandoz Launches Pyzchiva Biosimilar of J&J’s Stelara in US
Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson &...
Samsung Bioepis’ Ospomyv and Xbryk Gain FDA Approval for RANKL Inhibitor Biosimilars
South Korea-based Samsung Bioepis Co., Ltd. announced that it has received marketing approval from the...
Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market
South Korea’s Samsung Bioepis and Israel-based Teva Pharmaceutical (NYSE: TEVA) have entered into a license,...
Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe
US-based Biogen Inc. (NASDAQ: BIIB) and South Korea’s Samsung Bioepis Co., Ltd. have jointly announced...
Sandoz Inks Deal with Samsung Bioepis for Ustekinumab Biosimilar SB17
The Sandoz (SWX: SDZ) unit of Switzerland-based Novartis (NYSE: NVS) has announced the in-licensing of...